top of page

How Will FDA Guidance Impact Decentralized Clinical Trials in 2023?

The agency’s goal is to spur a macro shift in clinical trials. The FDA is trying to tell these companies what it wants to be different in trials across the board with regards to digital health endpoints, the use of real-world data (RWD) as regulatory-grade data, and diversity in clinical trial inclusion.


How Will FDA Guidance Impact Decentralized Clinical Trials in 2023? - MedCity News




bottom of page